がん治療用ジェネリック医薬品の世界市場：用量・価格・機会の考察

世界のがん治療用ジェネリック医薬品市場の売上は、2026年までに550億米ドルを上回り、指数関数的な成長が予測されています。

当レポートでは、世界のがん治療用ジェネリック医薬品市場について調査分析し、市場動向分析、市場機会、市場成長率、償還政策、セグメント別の分析、主要企業などについて、体系的な情報を提供しています。

目次

第1章 がん治療用ジェネリック医薬品のイントロダクション

第2章 世界のがん治療用ジェネリック医薬品の市場動向分析

• 概要
• 現在の市場シナリオ
• 市場の将来の見通し

第3章 米国 - がん治療用ジェネリック医薬品の現在の状況

• 重要ファクト・市場の数値
• 市場動向・機会

第4章 日本 - 現在のがん治療用ジェネリック医薬品市場の考察

• 市場成長の促進要因
• 市場動向・機会

第5章 欧州 - がん治療用ジェネリック医薬品市場の進歩に対する主な資産

• 成長に関連するファクトの評価
• 市場の現在の動向・機会

第6章 中国 - アジアにおける新興のがん治療用ジェネリック医薬品市場として

• 市場のファクト・数値のシミュレーション
• 市場の動向・機会

第7章 インド - 世界のジェネリック医薬品市場への主な貢献者

• 成長に関連するファクトシート
• 市場の動向・機会

第8章 韓国 - がん治療用ジェネリック医薬品市場の現在の考察

• 市場拡大のファクト・数値
• 市場の刺激的な動向・機会

第9章 ロシア - がん治療用ジェネリック医薬品市場のシナリオ

• 現在の市場状況を促進するファクト
• 動向・機会

第10章 償還政策・補償戦略

• 米国
• 欧州
• インド
• 日本
• 中国
• ロシア

第11章 価格分析 - ブランド医薬品 vs. ジェネリック医薬品

第12章 乳がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第13章 大腸がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第14章 白血病治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第15章 前立腺がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第16章 皮膚がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第17章 肺がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第18章 脳腫瘍治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第19章 腎細胞がん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第20章 複数のがん治療用ジェネリック医薬品 - 利用可能性・用量・価格分析

第21章 世界のがん治療用ジェネリック医薬品の市場力学

第22章 競合情勢

• Teva Pharmaceuticals
• Accord Healthcare
• Amneal Pharmaceuticals
• Mylan
• Dr. Reddy Laboratories
• Bedford Pharma
• Hikma
• Cipla
• Shilpa Medicare
• Fresenius Kabi
• Zydus Pharmaceuticals
• Neopharm
• Netco
• Mayne Pharma
• Alvogen
• Glenmark
• HBT Labs
• Gland
• Qilu Pharmaceuticals
• Akorn Pharmaceuticals
• MSN Group
• Wockhardt
• Rising Pharma
• Apotex
• Taro Pharmaceuticals
• Sun Pharma
• Alkem Laboratories
• Endo Pharma
• Pfizer (Hospira)

List of Figures

• Figure 1-1: Objectives of Cancer Generics for Cancer Patients
• Figure 1-2: Gleevec - Comparison between Branded & Generic Drug Price for 30 Tablets of 400 mg (US$), January'2020
• Figure 1-3: Key Differences Between Branded & Generic Drugs
• Figure 1-4: Global - Cost of Branded Drug vs. Generic Drug Development, (US$ Million)
• Figure 1-5: Cancer Generic vs. Branded Developmental Timeline
• Figure 1-6: Developmental Timeline for Branded Drug & Generic Drug (Years)
• Figure 2-1: Global - Pharmaceutical Market (US$ Trillion), 2018 - 2026
• Figure 2-2: Global - Size of Total Cancer Market vs. Cancer Generics Market (US$ Billion), 2018
• Figure 2-3: Global - Size of Total Cancer Market vs. Cancer Generics Market (%), 2018
• Figure 2-4: Global - Estimated Cancer Market vs. Cancer Generics Market (US$ Billion), 2018 - 2026
• Figure 2-5: Global - Expected Generics Market Size (US$ Billion), 2018 - 2025
• Figure 2-6: Global - Market Size of Cancer Generics (US$ Billion), 2018 & 2026
• Figure 2-7: Global - Estimated Market Size of Cancer Generics (US$ Billion), 2018 - 2026
• Figure 3-1: US - Total Cancer Deaths, 2018 & 2019
• Figure 3-2: US - Cancer Mortality Rate by Gender per 100,000 Person, 2018
• Figure 3-3: US - Cancer Statistics of Children of age 0 - 9 Years, 2017
• Figure 3-4: US - National Expenditure for Cancer Care (US$ Billion), 2015 & 2017
• Figure 3-5: US - Population Statistics (Million), 2018 & 2019
• Figure 3-6: US vs. ROW Population Statistics (%), 2019
• Figure 3-7: US - Prescription Share of Generic Drugs filled at less than US$ 20 (%), 2018
• Figure 3-8: US - Average Branded & Generic Drug Copy (US$), 2018
• Figure 3-9: US - Generic Medicine Utilization by Age (%), 2017
• Figure 3-10: US - Top Generic Drug Pharmaceutical Companies, 2019
• Figure 3-11: US - Expected Generic Drug Market Size (US$ Billion), 2018 - 2025
• Figure 3-12: US - Market of Prescription Spending (%), 2017
• Figure 3-13: US - Minimum & Maximum Generic Drug Prescriptions out of every 10 Prescriptions, 2017
• Figure 4-1: Japan - Cancer Statistics (Million), 2018
• Figure 4-2: Japan - Population Statistics (Million), 2018 - 2020
• Figure 4-3: Japan vs. ROW Population Statistics (%), 2019
• Figure 4-4: Japan - Expected Penetration of Generics Market in the Country US$ Billion%), 2017 & 2018
• Figure 4-5: Japan - Top Cancer Generics Pharmaceuticals
• Figure 4-6: Japan - Estimated Cancer Market Size (US$ Million), 2018 - 2026
• Figure 4-7: Japan - Expected Generic Market Size (US$ Billion), 2018 - 2026
• Figure 4-8: Japan - Market Representation by Generic Drugs (%), 2020
• Figure 4-9: Total Cancer Drug Market Global vs. Japan Cancer Drug Market (US$ Billion), 2019
• Figure 4-10: Generics Drug Market - Global vs. Japan (US$ Billion), 2019
• Figure 5-1: Europe - Population Statistics (Million), 2017 - 2019
• Figure 5-2: Europe - Population Statistics by Region (Million), 2020
• Figure 5-3: Europe vs. ROW Population Statistics (%), 2019
• Figure 5-4: Europe vs. Global Population (Million), 2018 & 2019
• Figure 5-5: Europe - Cancer Statistics (Million), 2018
• Figure 5-6: Europe - Pharmaceutical Sales (US$ Billion), 2018 - 2020
• Figure 5-7: Europe - Top Cancer Generics Pharmaceutical Companies
• Figure 5-8: Germany - Population Statistics (Million), 2018 - 2020
• Figure 5-9: Germany - Cancer Statistics (Million), 2018
• Figure 5-10: Germany - Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2026
• Figure 5-11: Germany - Expected Generics Market Size (US$ Billion), 2018 - 2026
• Figure 5-12: Germany - Penetration of Generics Market into Total Pharmaceutical Market (%), 2019
• Figure 5-13: Germany - Driving Factors for Generics Market
• Figure 5-14: France - Population Statistics (Million), 2017 - 2019
• Figure 5-15: France - Cancer Statistics (Million), 2018
• Figure 5-16: France - Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2026
• Figure 5-17: France - Expected Generics Market Size (US$ Billion), 2018 - 2026
• Figure 5-18: UK - Population Statistics (Million), 2017 - 2019
• Figure 5-19: UK - Cancer Statistics (Million), 2018
• Figure 5-20: UK - Expected Pharmaceutical Market Size (US$ Billion), 2018 - 2026
• Figure 5-21: UK - Expected Number of Generic Subscriptions Fulfilled (Million), 2018 - 2026
• Figure 5-22: Belgium - Estimated Pharmaceutical Market Size (US$ Billion), 2018 - 2026
• Figure 5-23: Belgium - Expected Generic Market (US$ Million), 2018 - 2026
• Figure 5-24: Belgium - Penetration of Generic Market in Total Pharmaceutical Market, 2019
• Figure 6-1: China - Population Statistics (Million), 2016 - 2020
• Figure 6-2: China vs. Global Population Statistics (%), 2019
• Figure 6-3: China - Cancer Statistics (Million), 2018
• Figure 6-4: China - Registered Drugs (%), 2019
• Figure 6-5: China - Generic Drug Application Procedure
• Figure 6-6: China - Top Pharmaceutical Companies
• Figure 6-7: China - Expected Total Pharmaceutical Market (US$ Billion), 2018 - 2025
• Figure 6-8: China - Estimated Cancer Market Size (US$ Million), 2018 - 2026
• Figure 6-9: China - Estimated Generics Market Size (US$ Billion), 2018 - 2026
• Figure 6-10: China -Pharmaceutical Market vs. Generics Market (US$ Billion), 2018 - 2026
• Figure 7-1: India - Population Statistics (Million), 2017 - 2019
• Figure 7-2: Total Population vs. Population of India (%), 2019
• Figure 7-3: India - Cancer Statistics (Million), 2018
• Figure 7-4: India - Expected Pharmaceutical Market Size (US$ Billion), 2018 - 2026
• Figure 7-5: India - Percentage of India's Pharmaceutical Market vs. Global, 2018
• Figure 7-6: India - Expected Pharmaceutical Export Market (US$ Billion), 2018 - 2025
• Figure 7-7: India - Estimated Cancer Drug Market (US$ Billion), 2018 - 2026
• Figure 7-8: India - Top Generic Drug Pharmaceutical Companies
• Figure 7-9: India - Expected Generic Market Size (US$ Billion), 2018 - 2026
• Figure 7-10: India - Exports of Generics (%), 2019
• Figure 7-11: Ibrunat - Price of Branded Drug vs. Generic Drug (US$), 2019
• Figure 7-12: Hertab - Price of Branded Drug vs. Generic Drug (US$), 2019
• Figure 8-1: South Korea - Population Statistics (Million), 2017 - 2019
• Figure 8-2: South Korea - Cancer Statistics (Million), 2018
• Figure 8-3: South Korea - Countries Buying Korean Drugs (US$ Million), 2018
• Figure 8-4: South Korea - Top Generic Drug Pharmaceutical Companies
• Figure 8-5: South Korea - Estimated Pharmaceutical Market (US$ Billion), 2018 - 2026
• Figure 8-6: South Korea - Cancer Drug Market Estimates (US$ Billion), 2018 - 2026
• Figure 8-7: South Korea - Expected Generics Market Size (US$ Billion), 2018 - 2026
• Figure 9-1: Russia - Population Statistics (Million), 2017 - 2019
• Figure 9-2: Russia - Cancer Statistics (Million), 2018
• Figure 9-3: Russia - Demographics of Cancer Deaths (Million), 2018 & 2035
• Figure 9-4: Russia - Estimated Pharmaceutical Market Size (US$ Billion), 2018 - 2026
• Figure 9-5: Russia - Domestic vs. International Pharmaceutical Volume Share (%), 2019
• Figure 9-6: Russia - Expected Domestic vs. International Pharmaceutical Value Share (%), 2019
• Figure 9-7: Russia - Estimated Generics Drug Market (US$ Billion), 2018 - 2026
• Figure 9-8: Russia - Share of Generics in the Total Pharmaceutical Market (%), 2018
• Figure 9-9: Russia - Average Cost of Branded v/s Generic Drug (US$), 2019
• Figure 9-10: Russia -Generic Drugs v/s Branded Drug Package Sales Volume (%), 2019
• Figure 10-1: South Korea - Population Enrolled vs. Not Enrolled under National Health Insurance, 2018
• Figure 10-2: South Korea - Population Enrolled vs. Not Enrolled under National Health Insurance (%), 2018
• Figure 11-1: Key Factors for Low Pricing of the Generic Drugs in the Market
• Figure 12-1: Letrozole - FDA & First Generic Approval Year
• Figure 12-2: Letrozole - Price for a Supply of 30 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-3: Letrozole - Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-4: Letrozole - Price for a Supply of 90 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-5: Letrozole - Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-6: Letrozole - Price Comparison of 30 Tablets Supply of Branded & Generic Letrozole (US$), 2020'January
• Figure 12-7: Letrozole - Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US$), 2020'January
• Figure 12-8: Anastarzole - FDA & Generic Approval Year
• Figure 12-9: Anastrazole - Price for a Supply of 6 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-10: Anastrazole - Price for a Supply of 15 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-11: Anastrazole - Average Price for a Supply of 30 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-12: Anastrazole - Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-13: Anastrazole - Average Price for a Supply of 90 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-14: Anastrazole - Price for a Supply of 500 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-15: Anastrazole - Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$), 2020'January
• Figure 12-16: Anastrazole - Price Comparison of 30 Tablets Supply of Branded & Generic Anastrazole (US$), 2020'January
• Figure 12-17: Letrozole - Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020'January
• Figure 12-18: Armidex - Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020'January
• Figure 12-19: Exemestane - FDA & First Generic Approval Year
• Figure 12-20: Exemestane - Price Comparison of 30 Tablets of Branded & Generic Exemestane (US$), 2020'January
• Figure 12-21: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
• Figure 12-22: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
• Figure 12-23: Epirubicine - FDA & First Generic Approval Year
• Figure 12-24: Epirubicine - Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US$), January'2020
• Figure 12-25: Epirubicine - Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US$), January'2020
• Figure 12-26: Ellence - Average Price for a Supply of 25ml & Price per ml of Intravenous Solution (US$), January'2020
• Figure 12-27: Ellence - Average Price for a Supply of 100ml & Price per ml of Intravenous Solution (US$), January'2020
• Figure 12-28: Epirubicine - Minimum & Maximum Duration of Breast Cancer Treatment (Weeks), January'2020
• Figure 12-29: Epirubicine - Average Cost of Single Treatment Cycle and Full Treatment using 120/m2 Dose Regimen (US$), January'2020
• Figure 12-30: Ellence - Average Cost of Single Treatment Cycle and Full Treatment using 120/m2 Dose Regimen (US$), January'2020
• Figure 12-31: Epirubicine - Average Cost of Single Treatment Cycle and Full Treatment using 100/m2 Dose Regimen (US$), January'2020
• Figure 12-32: Ellence - Average Cost of Single Treatment Cycle and Full Treatment using 100/m2 Dose Regimen (US$), January'2020
• Figure 12-33: Toremifene - FDA & First Generic Approval Year
• Figure 12-34: Toremifene - Price Comparison of 30 Tablets of Branded & Generic Toremifene (US$), 2020'January
• Figure 12-35: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
• Figure 12-36: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
• Figure 12-37: Fulvestrant - FDA & First Generic Approval Year
• Figure 12-38: Fulvestrant - Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$), January'2020
• Figure 12-39: Faslodex - Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$), January'2020
• Figure 12-40: Fulvestrant - Number of Dose Administration in Initial & Subsequent Months, January'2020
• Figure 12-41: Fulvestrant - Treatment Cost of Initial & Subsequent Months (US$), January'2020
• Figure 12-42: Fulvestrant - Treatment Cost of Initial & Subsequent Year (US$), January'2020
• Figure 12-43: Faslodex - Treatment Cost of Initial & Subsequent Months (US$), January'2020
• Figure 12-44: Faslodex - Treatment Cost of Initial & Subsequent Year (US$), January'2020
• Figure 12-45: Megastrol - FDA & Generic Approval Year
• Figure 12-46: Megastrol - Price for Various Supplies of 40mg/ml Oral Suspension (US$), January'2020
• Figure 12-47: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$), January'2020
• Figure 12-48: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$), January'2020
• Figure 12-49: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US$), January'2020
• Figure 12-50: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US$), January'2020
• Figure 12-51: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US$), 2020'January
• Figure 12-52: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US$), 2020'January
• Figure 13-1: Irinotecan - FDA & First Generic Approval Year
• Figure 13-2: Irinotecan - Price Comparison of 2ml Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 13-3: Irinotecan - Price Comparison of 5 ml Intravenous Branded & Generic Solution (US$), 2020'January
• Figure 13-4: Irinotecan - Price of 25ml & Price per ml of Intravenous Solution (US$), 2020'January
• Figure 13-5: Captostar - Price of 15ml & Price per ml of Intravenous Solution (US$), 2020'January
• Figure 13-6: Irinotecan - Minimum & Maximum Duration of Treatment Cycle (Weeks), January '2020
• Figure 13-7: Irinotecan - Cost of Single Treatment Cycle using Branded & Generic Irinotecan Intravenous Solution (US$), January '2020
• Figure 13-8: Oxaliplatin - FDA & First Generic Approval Year
• Figure 13-9: Oxaliplatin - Price of 50 mg & 100 mg Intravenous Powder for Injection (US$), 2020'January
• Figure 13-10: Oxaliplatin - Price of 10ml & 1ml Intravenous Solution for Injection (US$), 2020'January
• Figure 13-11: Oxaliplatin - Price of 20ml, 100ml & 200 ml Intravenous Solution for Injection (US$), 2020'January
• Figure 13-12: Eloxatin - Price of 10ml & 1ml Intravenous Solution for Injection (US$), 2020'January
• Figure 13-13: Eloxatin - Price of 20ml & 1ml Intravenous Solution for Injection (US$), 2020'January
• Figure 13-14: Oxaplatin - Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020'January
• Figure 13-15: Oxaplatin Powder - Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020'January
• Figure 13-16: Oxaplatin Solution - Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020'January
• Figure 13-17: Eloxatin - Average Cost of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (US$), 2020'January
• Figure 14-1: Clofarabin - FDA & First Generic Approval Year
• Figure 14-2: Clofarabin - Price Comparison of 20 ml Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 14-3: Clofrabin - Average cost of Single Treatment Cycle using Branded & Generic Solution (US$), january'2020
• Figure 14-4: Imatinib - FDA & First Generic Approval Year
• Figure 14-5: Imatinib - Price of 20 Tablets & Price per Unit of 100mg Tablet (US$), 2020'January
• Figure 14-6: Imatinib - Price of 30 Tablets & Price per Unit of 100mg Tablet (US$), 2020'January
• Figure 14-7: Imatinib - Average Price of 90 Tablets & Price per Unit of 100mg Tablet (US$), 2020'January
• Figure 14-8: Imatinib - Average Price of 20 & 30 Tablets Supply of 400mg Tablet (US$), 2020'January
• Figure 14-9: Gleevec - Price of 90 Tablets & Price per Unit of 100mg Tablet (US$), 2020'January
• Figure 14-10: Gleevec - Price of 30 Tablets & Price per Unit of 400mg Tablet (US$), 2020'January
• Figure 14-11: Imatinib - Dose in Chronic & Accelerated Phase of Mylogenous Leukemia (mg), January'2020
• Figure 14-12: Imatinib - Chronic Phase Treatment Cost Comparison using Branded & Generic Tablet (US$), January'2020
• Figure 14-13: Imatinib - Accelerated Phase Treatment Cost Comparison using Branded & Generic Tablet (US$), January'2020
• Figure 14-14: Mercaptopurine - FDA & First Generic Approval Year
• Figure 14-15: Mercaptopurine - Price of 25 Tablets & Price per Unit of 50mg Tablet (US$), 2020'January
• Figure 14-16: Mercaptopurine - Price of 250 Tablets & Price per Unit of 50mg Tablet (US$), 2020'January
• Figure 14-17: Mercaptopurine - Daily, Monthly & Annual Treatment Cost of ALL (US$), January'2020
• Figure 14-18: Idarubicin - FDA & First Generic Approval Year
• Figure 14-19: Idarubicine - Price Comparison of 5ml Intravenous Branded & Generic Solution (US$), 2020'January
• Figure 14-20: Idarubicine - Price Comparison of 10ml Intravenous Branded & Generic Solution (US$), 2020'January
• Figure 14-21: Idarubicine - Price Comparison of 20ml Intravenous Branded & Generic Solution (US$), 2020'January
• Figure 14-22: Idarubicin - Dialy & Maximum Cumulative Lifetime Dose (mg/m2), January'2020
• Figure 14-23: Idarubicin - Comparison of Dialy & Full Treatment Cost using Branded & Generic Tablet (US$), January'2020
• Figure 14-24: Cerubidine - FDA & First Generic Approval Year
• Figure 14-25: Daunorubicin - Price of 10 ml Supply & Price per ml of Intravenous Solution (US$), 2020'February
• Figure 14-26: Daunorubicin - Price of 40 ml Supply & Price per ml of Intravenous Solution (US$), 2020'February
• Figure 14-27: Daunorubicin - Number of Dose Administration in Initial & Subsequent Cycle for Acute Nonlymphocytic Leukemia, 2020'February
• Figure 14-28: Daunorubicin - Adult Dose for Acute Nonlymphocytic Leukemia by Age Group (mg/m2), 2020'February
• Figure 14-29: Daunorubicin - Cost of Single Dose for Nonlymphocytic Leukemia by Age Group (US$), 2020'February
• Figure 14-30: Cytarabin - Price for 25ml & 50ml Supply of 20mg/ml Intravenous Solution (US$), 2020'February
• Figure 14-31 Cytarabin - Price for 20ml Supply of 100mg/ml Intravenous Solution (US$), 2020'February
• Figure 14-32: Cytarabin - Average Minimum & Maximum Cost of Daily Treatment of Acute Nonlymphocytic Leukemia (US$), 2020'February
• Figure 14-33: Cytarabin - Average Daily & Full Treatment Cost in Initial Phase of Meningeal Leukemia (US$), 2020'February
• Figure 15-1: Abiraterone - FDA & First Generic Approval Year
• Figure 15-2: Aberaterone - Price of 30 Tablets & Price per unit of 250mg Tablet (US$), 2020'January
• Figure 15-3: Aberaterone - Price of 120 Tablets & Price per Unit of 250mg Tablet (US$), 2020'January
• Figure 15-4: Zytiga - Price of 120 Tablets & Price per unit of 250mg Tablet (US$), 2020'January
• Figure 15-5: Zytiga - Price of 60 Tablets & Price per Unit of 500mg Tablet (US$), 2020'January
• Figure 15-6: Abiraterone - Treatment Cost Comparison of Metastatic High-risk CSPC using Branded & Generic Tablet (US$), January'2020
• Figure 15-7: Abiraterone - Treatment Cost Comparison of Metastatic CSPC using Branded & Generic Tablet (US$), January'2020
• Figure 15-8: Bicalutamide - FDA & First Generic Approval Year
• Figure 15-9: Bicalutamide - Price Comparison of 30 Tablets of Branded & Generic Bicalutamide (US$), 2020'January
• Figure 15-10: Bicalutamide - Price of 100 Tablets & Price per Unit of 50mg Tablet (US$), 2020'January
• Figure 15-11: Bicalutamide - Price of 500 Tablets & Price per Unit of 50mg Tablet (US$), 2020'January
• Figure 15-12: Bicalutamide - Treatment Cost Comparison of Prostate Cancer using Branded & Generic Tablet (US$), January'2020
• Figure 15-13: Nilutamide - FDA & First Generic Approval Year
• Figure 15-14: Nilutamide - Price Comparison of 30 Tablets of Branded & Generic Nilutamide (US$), 2020'January
• Figure 15-15: Nilutamide - Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day), January'2020
• Figure 15-16: Nilutamide - Comparison of Initial Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US$), January'2020
• Figure 15-17: Nilutamide - Comparison of Maintenance Month Treatment Cost of Prostate Cancer using Branded & Generic Tablet (US$), January'2020
• Figure 15-18: Flutamide - FDA & First Generic Approval Year
• Figure 15-19: Flutamide - Price Comparison of 180 Capsules of Branded & Generic Flutamide (US$), 2020'January
• Figure 15-20: Flutamide - Comparison of Daily, Monthly & Annual Treatment of Prostate Cancer using Branded & Generic Capsule (US$), January'2020
• Figure 16-1: Aldara - FDA & First Generic Approval Year
• Figure 16-2: Imiquimod - Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US$), 2020'January
• Figure 16-3: Imiquimod - Price for a Supply of 24 Creams & Price per Unit of 5% Topical Cream (US$), 2020'January
• Figure 16-4: Aldara - Price for a Supply of 12 Creams & Price per Unit of 5% Topical Cream (US$), 2020'January
• Figure 16-5: Imiquimod - Duration of Single Treatment Cycle & Full Treatment of Basal Cell Carcinoma (Weeks), January'2020
• Figure 16-6: Imiquimod - Comparison of Single Treatment Cycle & Full Treatment using Branded & Generic 5% Cream (US$), January'2020
• Figure 16-7: Fluorouracil Cream - FDA & First Generic Approval Year
• Figure 16-8: Fluorouracil Solution - FDA & First Generic Approval Year
• Figure 16-9: Topical Fluorouracil - Price Comparison of 40gm Branded & Generic Cream (US$), 2020'January
• Figure 16-10: Topical Fluorouracil - Price of 10ml Supply & Price per ml of 5% Solution (US$), 2020'January
• Figure 16-11: Topical Fluorouracil - Minimum & Maximum Duration for Basal Cell Carcinoma Treatment (Weeks), 2020'January
• Figure 17-1: Vinorelbine - FDA & First Generic Approval Year
• Figure 17-2: Vinorelbine - Price Comparison of 5ml Supply of Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 17-3: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 17-4: Vinorelbine Monotherapy - Comparison of Treatment Cost of NSCLC using Branded & Generic Intravenous Solution (US$), January'2020
• Figure 17-5: Vinorelbine - Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January'2020
• Figure 18-1: Temozolomide Oral Capsule - FDA & First Generic Approval Year
• Figure 18-2: Temozolomide - Price of Various Supplies of 5mg Capsule (US$), 2020'January
• Figure 18-3: Temozolomide - Price of Various Supplies of 20mg Capsule (US$), 2020'January
• Figure 18-4: Temozolomide - Price of Various Supplies of 100mg Capsule (US$), 2020'January
• Figure 18-5: Temozolomide - Price of Various Supplies of 100mg Capsule (US$), 2020'January
• Figure 18-6: Temozolomide - Price of 5 Capsules Supply of 180mg & 250mg Dose (US$), 2020'January
• Figure 18-7: Temodar - Price of 5 & 14 Capsules Supplies of Different Dose Regimen (US$), 2020'January
• Figure 18-8: Temozolomide - Initial & Maintenance Dose for Anaplastic Astrocytoma (mg/m2), 2020'January
• Figure 18-9: Temozolomide - Anaplastic Astrocytoma Initial Treatment Cost Comparison using Branded & Generic Capsule (US$), January'2020
• Figure 18-10: Temozolomide - Anaplastic Astrocytoma Maintenance Treatment Cost Comparison using Branded & Generic Capsule (US$), January'2020
• Figure 18-11: Temozolomide - Gliobastoma Multiforme Treatment Cost Comparison using Branded & Generic Capsule (US$), January'2020
• Figure 19-1: Temsirolimus - FDA & First Generic Approval Year
• Figure 19-2: Vinorelbine - Price Comparison of 1ml Supply of Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 19-3: Temsirolimus- Comparison of Treatment Cost of Renal Cell Carcinoma using Branded & Generic Intravenous Solution (US$), January'2020
• Figure 20-1: Erlotinib - FDA & First Generic Approval Year
• Figure 20-2: Erlotinib - Price of 20 & 30 Tablets Supply of 25mg Dose (US$), 2020'January
• Figure 20-3: Erlotinib - Price of 20 & 30 Tablets Supply of 100mg Dose (US$), 2020'January
• Figure 20-4: Erlotinib - Price of 20 & 30 Tablets Supply of 150mg Dose (US$), 2020'January
• Figure 20-5: Tarceva - Price for 30 Tablets Supply of 25mg, 100mg & 150mg (US$), 2020'January
• Figure 20-6: Erlotinib - Comparison of Treatment Cost of NSCLC using Branded & Generic Tablet (US$), January'2020
• Figure 20-7: Erlotinib - Comparison of Treatment Cost of Pancreatic cancer using Branded & Generic Tablet (US$), January'2020
• Figure 20-8: Dactinomycin - FDA & First Generic Approval Year
• Figure 20-9: Dactinomycin - Price for a Supply 12 and Price for Single Powder for Injection (US$), 2020'January
• Figure 20-10: Dactinomycin - Price Comparison of 0.5mg Branded & Generic Powder for Injection (US$), 2020'January
• Figure 20-11: Dactinomycin - Cost Comparison of Single Treatment Cycle of Wilm's Tumor using Branded & Generic Powder for Injection (US$), 2020'January
• Figure 20-12: Dactinomycin - Cost Comparison of Testicular Cancer Treatment using Branded & Generic Dactinomycin (US$), January'2020
• Figure 20-13: Dactinomycin - Treatment Cost Comparison Lower Extremity Solid Tumor using Branded & Generic Powder for Injection (US$), 2020'January
• Figure 20-14: Ifosfamide - FDA & First Generic Approval Year
• Figure 20-15: Ifosfamide - Price Comparison of 1gm & 3gm Supply of Branded & Generic Powder for Injection (US$), 2020'January
• Figure 20-16: Ifosfamide - Price for a Supply 20ml & 60ml Intravenous Solution for Injection (US$), 2020'January
• Figure 20-17: Ifosfamide - Treatment Cost Comparison of Branded & Generic Powder fo Injection (US$), January'2020
• Figure 20-18: Istodax - FDA Approval & Patent Expiration Year
• Figure 20-19: Romidepsin - Price Comparison of 10mg Branded & Generic Powder for Injection (US$), 2020'January
• Figure 20-20: Remidepsin - Treatment Cost Comparison of Branded & Generic Dactinomycin (US$), January'2020
• Figure 20-21: Afinitor - FDA & First Generic Approval Year
• Figure 20-22: Evrolimus - Price of 28 Tablets Supplies of Various Dose Regimen (US$), 2020'January
• Figure 20-23: Afinitor - Price of 28 Tablets Supplies of Various Dose Regimen (US$), 2020'January
• Figure 20-24: Evrolimus - Treatment Cost Comparison of Various Cancers using Branded & Generic Tablet (US$), January'2020
• Figure 20-25: Capecitabine - FDA & First Generic Approval Year
• Figure 20-26: Capecitabine - Average Price for a Supply of 60 Tablets & Price per Unit of 150mg Tablet (US$), 2020'January
• Figure 20-27: Capecitabine - Average Price for a Supply of 20 Tablets & Price per Unit of 500mg Tablet (US$), 2020'January
• Figure 20-28: Capecitabine - Price for a Supply of 30 Tablets & Price per Unit of 500mg Tablet (US$), 2020'January
• Figure 20-29: Capecitabine - Average Price for a Supply of 120 Tablets & Price per Unit of 500mg Tablet (US$), 2020'January
• Figure 20-30: Capecitabine - Price Comparison of 60 Tablets Supply of 150mg Branded & Generic Capecitabine (US$), 2020'January
• Figure 20-31: Capecitabine - Price Comparison of 120 Tablets Supply of 500mg Branded & Generic Capecitabine (US$), 2020'January
• Figure 20-32: Capecitabine - Duration of Treatment & Rest Phase in Single Treatment Cycle (Weeks), 2020'January
• Figure 20-33: Capecitabine - Comparison of Treatment Cost of Breast Cancer using Branded & Generic Tablet (US$), January'2020
• Figure 20-34: Gemcitabine - FDA & First Generic Approval Year
• Figure 20-35: Gemcitabine - Average Price of 200mg, 1gm & 2gm Powder for Injection (US$), 2020'January
• Figure 20-36: Gemzar - Average Price of 200mg & 1gm Powder for Injection (US$), 2020'January
• Figure 20-37: Gemcitabine - Average Price for Supply of 5.26ml, 26.3ml & 52.6 ml Solution for Injection of 38mg/ml (US$), 2020'January
• Figure 20-38: Gemcitabine - Average Price of 2ml, 10ml, 15ml & 20ml Intravenous Solution (US$), 2020'January
• Figure 20-39: Gemcitabine - Treatment Cost Comparison of Ovarian Cancer using Branded & Generic Solution (US$), January'2020
• Figure 20-40 Gemcitabine - Treatment Cost Comparison of NSCLC & Breast Cancer using Branded & Generic Solution (US$), January'2020
• Figure 20-41: Taxol - FDA & First Generic Approval Year
• Figure 20-42: Paclitaxel - Average Price Various Supplies of Intravenous Solution for Injection (US$), 2020'January
• Figure 20-43: Paclitaxel - Dose for Treatment of Breast Cancer, NSCLC & Ovarian Cancer (Mg/m2/3 Weeks), 2020'February
• Figure 20-44: Paclitaxel - Average Cost of single Dose & Annual Treatment of Breast Cancer (US$), 2020'February
• Figure 20-45: Paclitaxel - Average Cost of Single Dose & Full Treatment of Adjuvant Breast Cancer (US$), 2020'February
• Figure 20-46: Adrucil - FDA & First Generic Approval Year
• Figure 20-47: Fluorouracil - Average Price of various Supplies of Intravenous Solution (US$), 2020'January
• Figure 20-48: Adrucil - Average Price of various Supplies of Intravenous Solution (US$), 2020'January
• Figure 20-49: Fluorouracil - Duration of Single Treatment cycle & Full Treatment of Breast Cancer (Weeks), 2020'January
• Figure 20-50: Fluorouracil - Treatment Cost Comparison of Breast Cancer using Branded & Generic Intravenous Solution (US$), 2020'January
• Figure 20-51: Fluorouracil - Branded v/s Generic Initial Day Treatment Cost Comparison of Colorectal Cancer (US$), 2020'January
• Figure 20-52: Fluorouracil - Branded v/s Generic Subsequent Treatment Cycle Cost Comparison of Colorectal Cancer (US$), 2020'January
• Figure 20-53: Docetaxel - FDA & First Generic Approval Year
• Figure 20-54: Docetaxel - Average Price of Various Supplies of Intravenous Solution of 10mg/ml Dose (US$), 2020'February
• Figure 20-55: Docetaxel - Average Price of various Supplies of Intravenous Solution of 20mg/ml Dose (US$), 2020'February
• Figure 20-56: Taxotere - Average Price for 1ml & 4 ml Supplies of Intravenous Solution (US$), 2020'February
• Figure 20-57: Docetaxel - Treatment Cost Comparison of Branded & Generic Drug for Prostate Cancer & NSCLA (US$), 2020'February
• Figure 20-58: Docetaxel Combination - Duration of Single Treatment Cycle & Full Treatment of Breast Cancer (Weeks), 2020'February
• Figure 20-59: Docetaxel - Treatment Cost Comparison of Branded & Generic Drug for Breast Cancer Management (US$), 2020'February
• Figure 20-60: Methotrexate - Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), 2020'February
• Figure 20-61: Methotrexate - Average Price of Different Supplies of Oral Tablet (US$), 2020'February
• Figure 20-62: Methotrexate - Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), 2020'February
• Figure 20-63: Methotrexate - Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), 2020'February
• Figure 20-64: Methotrexate - Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), 2020'February
• Figure 20-65: Methotrexate - Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), 2020'February
• Figure 20-66: Methotrexate - Minimum & Maximum Treatment Cost of Single Day (US$), 2020'February
• Figure 20-67: Methotrexate - Minimum & Maximum Cost of Single Treatment Cycle (US$), 2020'February
• Figure 20-68: Cyclophosphamide - Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), 2020'February
• Figure 20-69: Cyclophosphamide - Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), 2020'February
• Figure 20-70: Cyclophosphamide IV Solution - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), 2020'February
• Figure 20-71: Cyclophosphamide Capsule - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), 2020'February
• Figure 20-72: Vincristine - Average Price for 1ml & 2ml Intravenous Solution (US$), 2020'February
• Figure 20-73: Vincristine - Average Cost of Single Cycle, Monthly & Annual Treatment (US$), February'2020
• Figure 20-74: Vincristine - Minimum & Maximum Pediatric Dose (mg/m2), February'2020
• Figure 20-75: Etoposide - FDA & First Generic Approval Year
• Figure 20-76: Etoposide - Price for a Supply of 5 ml, 25 ml & 50 ml Supply of Intravenous Solution (US$), February'2020
• Figure 20-77: Etoposide - Price for a Supply of 20 Tablets & Price per Unit of 50 mg Tablet (US$), February'2020
• Figure 20-78: Etoposide - Minimum & Maximum Duration of Single Treatment Cycle of SCLC (Weeks), February'2020
• Figure 20-79: Etoposide - Average Cost of Daily Treatment & One Treatment Cycle of SCLC (US$), February'2020
• Figure 20-80: Etoposide - Minimum & Maximum Cost of Single Treatment Cycle of Testicular Cancer (US$), February'2020
• Figure 20-81: Mitoxantrone - FDA & First Generic Approval Year
• Figure 20-82: Mitoxantrone - Price for a Supply of 10 ml, 12.5 ml & 15 ml Supply of Intravenous Solution (US$), February'2020
• Figure 20-83: Mitoxantrone - Average Cost of Single Treatment Cycle & Annual Treatment of Prostate Cancer (US$), February'2020
• Figure 20-84: Mitoxantrone - Average Cost of Induction & Consolidation Phase for Acute Non-Lymphocytic Leukemia (US$), February'2020
• Figure 20-85: Carmustine - FDA & First Generic Approval Year
• Figure 20-86: Carmustine - Branded v/s Generic Price Comparison of 100mg Dose (US$), February'2020
• Figure 20-87: Etoposide - Minimum & Maximum Cost of Single Treatment Cycle (US$), February'2020
• Figure 20-88: BiCNU - Minimum & Maximum Cost of Single Treatment Cycle (US$), February'2020
• Figure 20-89: Dacarbazine - FDA & First Generic Approval Year
• Figure 20-90: Dacarbazine - Price for a Supply of 10 & Price per Unit of 100 mg Powder for Injection (US$), February'2020
• Figure 20-91: Dacarbazine - Price for a Supply of 20 & Price per Unit of 200 mg Powder for Injection (US$), February'2020
• Figure 20-92: Dacarbazine - Minimum & Maximum Dose for Malignant Melanoma (mg/m2/day), February'2020
• Figure 20-93: Dacarbazine - Minimum & Maximum Cost of One Treatment Cycle for Malignant Melanoma (US$), February'2020
• Figure 20-94: Dacarbazine - Cost of Single Dose & Single Treatment Cycle for Malignant Melanoma (US$), February'2020
• Figure 20-95: Miytomycin - FDA & First Generic Approval Year
• Figure 20-96: Mitomycin - Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US$), February'2020
• Figure 20-97: Mutamycin - Price for Supply of Single 5mg, 20 mg & 40 mg Powder for Injection (US$), February'2020
• Figure 20-98: Mitomycin - Minimum & Maximum Duration of Single Treatment Cycle (Weeks), February'2020
• Figure 20-99: Mitomycin - Branded v/s Generic Cost Comparison of Single Treatment Cycle (US$), February'2020
• Figure 20-100: Bleomycin - FDA & First Generic Approval Year
• Figure 20-101: Bleomycin - Price for Supply of Single 15 Units & 30 Units Powder for Injection (US$), February'2020
• Figure 20-102: Bleomycin - Minimum & Maximum Cost for Single Once a Week Treatment Cycle (US$), February'2020
• Figure 20-103: Bleomycin - Minimum & Maximum Cost for Single Twice a Week Treatment Cycle (US$), February'2020

"Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

• Global Cancer Generics Market Trend Analysis

• Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026

• Global Generics Market Growth 2018-2026: > 130%

• Global Cancer Generics Market Growth 2018-2026: 200%

• Reimbursement Policies & the Coverage Strategies By Countries

• Cancer Generic Drugs Availability, Dosage & Price Analysis By Segment

• Comprehensive Insight On Cancer Generics Drugs: 43 Generics

Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality. The major advantage that is largely associated with the accelerated generics drug market is the fact that the development of the drug doesn't require prolonged period of time. The ease in developing the drug and the high adoption rate by the patients contribute largely to the established markets of cancer generics.

"The Global Cancer Generic Drug Market To Witness Exponential Growth As Drug Sales Are Expected To Increase Its Sales Beyond US$ 55 Billion By 2026"

It is well witnessed fact that the survival rate of the cancer patients have experienced a positive trail since the advent of the cancer generic drugs in the market. Patients and clinicians, whenever possible are more inclined towards the utilization of generic drugs in their treatment, as it is more segmented towards the patients that are not able to consume branded drugs, which however comprises of the maximum population around the globe. The necessity of generic drugs in the society and the upsurge it has been experiencing since its arrival at the global pharmaceutical landscape represents a stage of the market which is highly dominated by the cancer generics drugs.

Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive. The most important and the fundamental advantages that are received by the approach is that it provides the bioequivalent form of the original branded drug i.e. in same dosage, mode of administration and the effectiveness in a way cheaper price. Such advantages are making the whole percentage of patients with no or less hope towards a more suitable and decent method by providing a privileged from of treatment.

The increasing consumption of the generic drugs and the mounting trust of patient towards cancer generics drugs are going to play a very important role in the market expansion. A big contribution for the splendid market growth rate is also provided by the governing bodies of the respective country. The impositions made by the governing bodies for clinicians in dispensing generic drugs have caused an accelerated growth in the market size. The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

The research report “Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026” provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe. The research report is a result of the extensive study conducted by analyzing the global companies for cancer generics. The opinions from the different generic drug companies have been gathered to successfully deliver the latest trends and opportunities and the future prospects on commercials for the market of cancer generics.

Table of Contents

1. Introduction to Cancer Generics

• 1.1. Overview
• 1.2. The Growing Need for Cancer Generics over Branded Drugs
  • 1.2.1. Reduced Developmental Cost Leading to Cost-Efficient Cancer Generics
  • 1.2.2. Reduced Timeline Leading to Cost-Efficient Cancer Generics Development
  • 1.2.3. Cancer Generics Representing Same Effectiveness as of Branded Drugs

2. Global Cancer Generics Market Trend Analysis

• 2.1. Overview
• 2.2. Current Market Scenario
• 2.3. Cancer Generics Market Future Outlook

3. US-Current Market Status of Cancer Generics

• 3.1. Significant Facts & Figures Prevailing Cancer Generics Market
• 3.2. US Cancer Generics Market Trends & Opportunities
  • 3.2.1. Guidelines, Policies & Procedures by the FDA for the US Market

4. Japan-Current Cancer Generics Market Insight

• 4.1. Factors Propelling the Growth of Cancer Generics in Japan
• 4.2. Trends & Opportunities of Cancer Generics Market in Japan
  • 4.2.1. Cancer Generic Drugs Prescription & Dispensing

5. Europe-Key Asset to Cancer Generics Market Progression

• 5.1. Evaluation of Facts Associated with Cancer Generics Growth
• 5.2. Cancer Generics Market Current Trends & Opportunities
  • 5.2.1. Europe Government Regulations for Cancer Generics Market Progress
  • 5.2.2. Germany-Current Cancer Generics Market Trends & Opportunities
  • 5.2.3. France-Current Cancer Generics Market Trends & Opportunity
  • 5.2.4. UK-Current Cancer Generics Market Trends & Opportunities
  • 5.2.5. Belgium-Current Cancer Generics Market Trends & Opportunities
  • 5.2.6. Others-Current Cancer Generics Market Trends & Opportunities

6. China-As a Emerged Cancer Generic Market in Asia

• 6.1. Simulating Facts & Figures for Chinese Cancer Generics Market
• 6.2. Trends & Opportunities Linked with China's Cancer Generics Market
  • 6.2.1. Laws & Regulating Supporting Cancer Generics Market in China

7. India-A Major Contributor to the Global Generics Market

• 7.1. Fact Sheets Related to Cancer Generics Growth in India
• 7.2. Trends & Opportunities for India's Cancer Generics Market
  • 7.2.1. Guidelines & Laws for Implementing Generic Drugs in India

8. South Korea-Cancer Generics Market Current Insight

• 8.1. Cancer Generics Drug Market Expansion Facts & Figures
• 8.2. Provoking Trends & Opportunities for South Korean Cancer Generics Market

9. Russia-Cancer Generics Market Scenario

• 9.1. Facts Encouraging the Current Market Situation in Russia
• 9.2. Trends & Opportunities Followed by Russian Cancer Generics Market
  • 9.2.1. Rules & Regulations Boosting the Current Market of Cancer Generics

10. Reimbursement Policies & the Coverage Strategies

• 10.1. US
• 10.2. Europe
• 10.3. India
• 10.4. Japan
• 10.5. China
• 10.6. Russia

11. Price Analysis for Branded Drugs VS Generic Drugs

12. Breast Cancer Generic Drugs-Availability, Dosage & Price Analysis

• 12.1. Letrozole
• 12.2. Anastrazole
• 12.3. Exemestane
• 12.4. Epirubicine
• 12.5. Toremifene
• 12.6. Fulvestrant
• 12.7. Megestrol

13. Colorectal Cancer Generic Drugs-Availability, Dosage & Price Analysis

• 13.1. Irinotecan
• 13.2. Oxaliplatin

14. Leukemia Generic Drugs-Availability, Dosage & Price Analysis

• 14.1. Clofarabin
• 14.2. Imatinib
• 14.3. Mercaptopurine
• 14.4. Idarubicin
• 14.5. Daunorubicin
• 14.6. Cytarabin

15. Prostate Cancer Generic Drugs-Availability, Dosage & Price Analysis

• 15.1. Abiraterone
• 15.2. Bicalutamide
• 15.3. Nilutamide
• 15.4. Flutamide

16. Skin Cancer Generic Drugs-Availability, Dosage & Price Analysis

• 16.1. Imiquimod Topical Cream
• 16.2. Fluorouracil Topical

17. Lung Cancer Generic Drugs-Availability, Dosage & Price Analysis

• 17.1. Vinorelbine

18. Brain Tumor Generic Drugs-Availability, Dosage & Price Analysis

• 18.1. Temozolomide

19. Renal Cell Carcinoma Generic Drug-Availability, Dosage & Price Analysis

• 19.1. Temsirolimus

20. Generic Drugs for Multiple Cancers-Availability, Dosage & Price Analysis

• 20.1. Erlotinib
• 20.2. Dactinomycin
• 20.3. Ifosfamide
• 20.4. Romidepsin
• 20.5. Everolimus
• 20.6. Capecitabine
• 20.7. Gemcitabine
• 20.8. Paclitaxel
• 20.9. Fluorouracil
• 20.10. Docetaxel
• 20.11. Methotrexate
• 20.12. Cyclophosphamide
• 20.13. Vincristine
• 20.14. Etoposide
• 20.15. Mitoxantrone
• 20.16. Carmustine
• 20.17. Dacarbazine
• 20.18. Mitomycin
• 20.19. Bleomycin

21. Global Cancer Generics Market Dynamics

• 21.1. Factors Favoring the Growth of Cancer Generics Market
• 21.2. Factors Restraining the Growth of Cancer Generics Market

22. Compititive Landscape

• 22.1. Teva Pharmaceuticals
• 22.2. Accord Healthcare
• 22.3. Amneal Pharmaceuticals
• 22.4. Mylan
• 22.5. Dr. Reddy Laboratories
• 22.6. Bedford Pharma
• 22.7. Hikma
• 22.8. Cipla
• 22.9. Shilpa Medicare
• 22.10. Fresenius Kabi
• 22.11. Zydus Pharmaceuticals
• 22.12. Neopharm
• 22.13. Netco
• 22.14. Mayne Pharma
• 22.15. Alvogen
• 22.16. Glenmark
• 22.17. HBT Labs
• 22.18. Gland
• 22.19. Qilu Pharmaceuticals
• 22.20. Akorn Pharmaceuticals
• 22.21. MSN Group
• 22.22. Wockhardt
• 22.23. Rising Pharma
• 22.24. Apotex
• 22.25. Taro Pharmaceuticals
• 22.26. Sun Pharma
• 22.27. Alkem Laboratories
• 22.28. Endo Pharma
• 22.29. Pfizer (Hospira)